The vaccine maker reduced its 2022 guidance to a maximum of $2.3 billion, down from its previous estimate for as much as $5 billion.
The vaccine maker reduced its 2022 guidance to a maximum of $2.3 billion, down from its previous estimate for as much as $5 billion.